


KolGO Trg

**Kolkata Gynecological Oncology
Trials and Translational Research Group**



ANNUAL REPORT

2021-2022

Research and other activities during the financial year 2021-2022:

Kolkata Gynecological Oncology Trials and Translational Research Group (KolGO Trg) is a Gynecological Cancer Research Group based in Kolkata, India and the only member of GCIG from South-East Asia. KolGO Trg is motivated and driven by the purpose of promoting excellence in the quality and integrity of clinical and translational scientific research in the field of Gynecologic Cancers to provide better alternatives.

Given below different project achievements/advancements:

NuGenA

Nurse-led Genetic counselling in improving Awareness and implementation of screening services for hereditary women's cancer

Objectives:

We are proposing a strategy where a nurse led genetic counselling service (intervention) whereby nurses/medical social workers after adequate training, will develop a community-based program for health education, cancer awareness and genetic counselling/referral services in Eastern India. This model has not been evaluated in Eastern India before and can be an exemplar of a cost-effective approach of involving both the provider and acceptor of existing cancer health services to improve primary and secondary prevention in women's cancer. The key aim of this proposal is to evaluate whether such strategy will be acceptable, cost-effective, and scalable for all stakeholders i.e., patients, health care professionals, government/policy makers across diverse health infra- structural landscapes in low middle-income countries

We have developed KolGOTrg database in REDCap, NuGenA leaflet and SOP.

Data update:

- Number of nurses educated/trained: 56
- Genetic counselling module developed: 3
- Awareness camps done: 2
- Patient public involvement/PPP model done: 1

No. Of women counselled for NuGenA achievements till date:

- NuGenA- named Charter champion project at the World Ovarian Cancer Launch at IGCS 2020 meeting
- KolGoTrg received Charter champion award by WOCC- Oct 2020 where NuGenA was mentioned.

- NuGenA study and participants share the International stage on a dedicated program on hereditary women's cancer organised by WOCC- November 2021 with social media outreach.
- NuGenA study presented at the AOGIN 2021 Conference December 2021

HIPEC

Study objectives

The first aim of this study is to investigate whether the addition of an abdominal flush with chemotherapy. During surgery has an effect on staying away from the disease for longer. Another aim of the study is to investigate whether the extra treatment (the flushing of the abdominal cavity) has beneficial or adverse effects on the quality of life. That is why you are asked to complete so-called Quality of Life questionnaires.

Quality of life

In order to identify the impact of the study on your physical as well as emotional well-being you will be asked to fill up the quality of life questionnaires. It comprises of some questions to assess your physical, psychosexual, emotional and sexual wellbeing. You will be asked to complete these questionnaires before the surgery, 6 weeks after the surgery and then at every 6 months for a duration of total 5 years. A research nurse will assist you to fill up the questionnaire. The questionnaires can be either filled during your visit to the hospital or via telephone. You will be therefore asked to provide your details to the research nurse before enrolment in the study.

IPIROC

Intermittent PARP Inhibitor in Recurrent Ovarian Cancer

Ovarian cancer treatment is a looming pandemic in India where over 30,000 women die each year, and its incidence is increasing rapidly. PARP inhibitors (PARPi) have radically changed targeted therapies for cancers with BRCA mutations or homologous-recombination deficiency (HRD) in ovarian cancers. However, the recommended daily dosing of PARPi is unfeasible for the Indian/resource adapted patient cohort where low BMI and anemia is prominent. KolGO Trg's study, IPIROC aims at facilitating the access of life saving drug Rucaparib, such that it is equally accessible to every women affected with Ovarian Cancer worldwide, thus addressing financial and health toxicity without compromising survival.

Currently, we are carrying on with our Proof of Concept Exploratory study for determining the best cohort who would get benefited from this intermittent dosing. Next, we plan to expand our study to

a Randomized Controlled Phase 2 study to conduct a prospective pragmatic study in ovarian cancer patients, prescribed daily dosing of rucaparib and study tolerability, toxicity, efficacy, quality of life, affordability/cost-effectiveness, willingness to pay and patient satisfaction to a daily dosing schedule in the Indian population.

Weekly scientific meeting:

Date: 06/03/2021	Theme: Introduction and Cervical Cancer Group KolGo Trg	Participants: Members KolGo Trg Chair: Asima Mukhopadhyay
Agenda	Discussion points	Deliverables within 4 weeks
1. Cervical Cancer Research direction	Introduction to Group Structure Brainstorm for KolGo Trg cervical cancer projects	<ol style="list-style-type: none"> 1. Present a framework for clinical translational research in recurrent cervical cancer 2. Application for CCRN grant 3. Develop work plan for collaboration with Curie
Date: 13/03/2021	Theme: Clinical Trials	Participants: Members KolGo Trg Chair: Rahul RoyChowdhury
Agenda	Discussion points	Deliverables within 4 weeks
1. HOTROC study	Statistical considerations discussed with Dr Abhijit Hazra regarding sample size calculation options using 3 months increase in time to progress (restricted mean of survival difference) vs. progression rates at fixed intervals i.e., 6 months and 12 months since randomisation/ start of therapy. Also other endpoints like time to subsequent therapy discussed. Asima Mukhopadhyay will also contact Sanjoy Paul	<p>Present at next meeting the possible statistics and GCIG presentation</p> <p>Start looking for grant applications like ICMR</p> <p>Ethics has been obtained from CNCI an SGCCRI</p> <p>CTRI/ HMSC after final protocol</p> <p>Mou to develop the protocol guided by previous KolGo Trg/ INTERLACE and Astra templates for drug trials</p>
2. INTERLACE study	Dr Rahul RoyChowdhury discussed the practical considerations for INTERLACE in India in view of body habitus, bowel preparation Dr Ranajit Mandal will start recruitment soon at CNCI Staff support at CNCI and SGCCRI towards implementation of INTERLACE discussed	Present update in next meeting

Date: 20/03/2021	Theme: Ovarian Cancer Translational	Participants: Members KolGo Trg Chair: Susanta RoyChowdhury
Agenda	Discussion points	Deliverables within 4 weeks
Ovarian cancer Research direction	<ol style="list-style-type: none"> 1. Need to identify core member group from SGCCRI, CNCI, IICB for active participation in translational research. 2. The PI- Co-PI s of the group selected will run this program 3. There will be 3 (tentative) common translational/research theme contributed by the PI's: <ol style="list-style-type: none"> a. DDR/ PARP inhibitor axis area b. ImmuneInflammation/metabolism/microenvironment modulation c. Stromal cellular heterogeneity/CAF/stem cell/EMT plasticity 4. All the PI's should have some applied angles on whatever topic they choose to research 5. Publications on common theme of the research areas discussed 	Identify core group members for each theme who will be willing to develop and execute KolGoTrg projects and not individual projects to be supported by KolGo Trg as publication will be KolGo publications
Biobanking	<p>Possible framework for NABL accreditation and audit discussed by Shuvojit Moulik</p> <p>Members willing to use KolGo biobank must apply and cost it through their projects</p> <p>Ethics to be discussed. At present KolGo has MTA and MOU with individual institutes who will have project specific Ethics</p>	Asima to provide Newcastle biobank SOPs and audit tools to develop organisational and operational functioning- update will be presented at next meeting
Grant applications	<p>Dr. Damayanti and Dr. Shuvojit to discuss on the WBDBTST project write-up where Dr. Sushanta guided on the possible patient cohort; population based cohort- Kalyani area and hospital based cohort- CNCI, SGCCRI</p> <p>Asima discussed interaction with DBT and DBT IA to apply for the Team science grant and CRUK-DBT project on IPIROC study</p>	<p>Dr. Damayanti and Dr. Shuvojit to discuss on HRD assay, cell lines</p> <p>Grant submission update to be discussed at next meeting</p>

Date: 27/03/2021	Theme: Prevention and observational studies	Participants: Members KolGo Trg Chair: Ranajit Mandal
Agenda	Discussion points	Deliverables within 4 weeks
1. NuGenA study	Project proposal, update and recruitment strategy discussed by Dona Chakrabarty and Asima Mukhopadhyay	CTRI, HMSC application Grant applications WBDSTBT- discussed with Sharmila Sengupta re. inclusion of Kalyani cohort Manuscripts in preparation Will request SGCCRI to participate
2. Point of care HPV study	Dr Asima Mukhopadhyay discussed proposed collaboration with Cepheid India and meeting with International team to start a project on gene Xpert HPV testing in North Bengal tea garden workers Proposal submitted and pilot will be funded Sankhadeep to develop parallel translational studies and involve PhD students	Present update in next meeting RRC to approach tea board members to scale up/ support this study
3. AI study in cervical cancer screening	Dr Sharmila Sengupta and Ranajit Mandal discussed the respective DBT funded studies and areas in integration. PRESCRIP-TEC study to use Kalyani Cohort 1000 patients. Other 1000 patients will be recruited through 2 other models- existing CNCI model and snowballing method as defined in the protocol	Update in next meeting
4. Combined manuscript	Dr Sharmila Sengupta and Ranajit Mandal discussed the development of a combined manuscript on regional efforts for cervical cancer prevention towards achieving WHO elimination goals. Am volunteered to present a backbone of the strategy	Update next meeting

25th March 2022**Topic of Discussion and Speaker**

5.30pm-7.30 pm	IGCS-KolGO Trg meeting : PARP inhibitor in ovarian cancer Didactic: Prof Robert Coleman after IGCS ECHO TB Brainstorming session: KolGoTrg studies for LMICs (OCRN) and IPIROC study (KolGoTrg) - Asima Mukhopadhyay
7.30-8.30 pm	Education Committee update GCIG Young investigator program and IGCS fellowship in Kolkata- Asima Mukhopadhyay IGCS global curriculum program and researcher development- Linus Chuang, Joseph Ng, Kathleen Schmeler Quality of life/Symptom Benefit and Health Economic study Committee update Every Women Study- LMIC- Frances Reid Asima Mukhopadhyay (SOCQER IND/ HEPTRC and Willingness to pay studies) and Sudha Sundar

26th March 2022

2:00pm- 3:00pm	Vulval cancer study ideas – Neville Hacker, Kailash Narayan
3:00pm-5.00pm	Cervical and Endometrial Cancer Committee: Participation in International studies (INTERLACE/SENTICOL/CERVENTES):Ranjit Mandal, ManishaVernekar, Asima Mukhopadhyay New concept Brain storming- Using molecular insights for an Endometrial cancer trial in LMICs– Rahul Roy Chowdhury, Anitha Thomas, Ranjit Manchanda, Angela Ralte New Concept Brain storming- Puja Chatterjee, Amitabha Ray, Koustav Majumdar, Asima Mukhopadhyay. Mentor- Kailash Narayan, Thomas Ram, Mary McCormack - ReCerCa (Recurrent cervical cancer) - BRICA (Neoadjuvant chemo in bladder / rectal involvement in cervical cancer) PARP RAD (PARPi as radiosensitizer) studies

6 pm-7.30 pm

Prevention and screening committee (proposed studies with international participation/ outreach):

- Integration of ongoing AI in cervical cancer screening studies in the region
Compilation manuscript for cervical cancer prevention effort in the region over last 20 years - Sharmila Sengupta and Ranajit Mandal.
- Nurse led Geneticcounselling and Awareness for hereditary women's cancer- NuGenA study- Asima Mukhopadhyay, Ranjit Manchanda, Dona Chakrabarty, Smritikana Mani
- PreCerCa (Prevention of cervical cancer study with point of care testing)- Asima Mukhopadhyay, Neerja Bhatla, Nisha Singh, Bindiya Gupta, Debkishore Gupta, Priyanka Singh.
- New concept- BIODIVARSITY(Breast Ovarian Cancer Diverse Arsenic exposure study) and PREGNANCY (peripartum prevention of gynecological malignancy)- Asima Mukhopadhyay

Epidemiological study concepts in the region for cancer prevention- Syam Sundar Mandal.

7.30pm- 8.30 pm

E-meet and greet session: Donors, Patrons and Members, academic partners and Sarbojaya(KolGoTrg survivorship) group

27th March

Translational day (Hybrid meeting)

10.30am–12.00pm

Virtual: Statistical committee update and directions: Sanjoy Paul and KolGo Group (Closed meeting: Membership, Finance)

2 pm- 3.30 pm

Translational Committee ideas and international participation
Cervical cancerAPGOT session: Sharmila Sengupta, Sankhadeep Dutta, Chinmoy Panda, APGOT team

3.30- 4.30pm

Endometrial cancer- Rahul RoyChowdhury, Damayanti Das Ghosh, Susanta RoyChoudhury

5:00pm-7:00pm

Ovarian cancer ideas (Team Science approach)-

1. 3 D models and international biobank update- Damayanti Das Ghosh,ShuvojitMoulik, Santosh Guru, Sanjiban Chakrabarty
2. Tumour micro-environment- Sibsankar Roy,Shilpak Chatterjee, Kaushik Sengupta, Chandan Mandal, Saptak Banerjee, Nabanita Chatterjee, Tanya Das, BiswarupBasu (Developing the Team Science

- grant)
3. PARP inhibitor studies : Session sponsor (Zydus)

Real world data in India

Translational studies on IPIROC study-discussion- **Iain McNeish , Nicola Curtin, Michael Bookman**

Made in India PARP study (MoRePARP)- morbidity reduction with PARPi (translational concepts)- IICB Kolkata

Functional HRD assay update- Susanta Roy Choudhury, Asima Mukhopadhyay, Benubrata Das (HRD, PARP, p53), Dipanjan Chowdhury **Session sponsor (Suraksha Diagnostics)**

7.00pm-8.00 pm

Future directions and Conclusions:

Biman Chakraborty, Susanta Roychoudhury, Chitra Mandal, Chanchal Goswami, Santanu Tripathi

Launch of The ROCK (Regional Ovarian Cancer Centre Kolkata) group- Asima Mukhopadhyay

8.00 pm onwards

Closure and Dinner

Achievements:

1. Full GCIG membership and GCIG badged studies from India- IPIROC
2. Participate in GCIG studies- INTERLACE, SENTICOL and preparation to enrol in DEBULK, CERVENTES, CONTESSA, OVIHIPEC 2, FLORA 5
3. Participation in 6th OCCC, printed in Lancet oncology, and Phase 2 brainstorming session
4. IGCS collaboration, as external partners- IGCS fellowship at CNCI and SCGGRI as the Kolkata Cluster (hub and spoke model) and plans for expansion including mentoring Nepal, Bangladesh and other Indian sites
5. GCIG-IGCS young investigator program: Manisha and Puja to be enrolled in the programme
6. IGCS support to KolGOTrg for mentorship and training program
7. WOCC collaboration: attending the consensus meeting for affordable medicines worldwide, EWS
8. ICRI collaboration for training program: MOU signed and training will start shortly
9. DSIR certification
10. Expansion of collaborating sites in India- Lucknow, Delhi, Bangalore, Vellore; Prof Lalit Kumar, Prof Sudeep Gupta to join as life member
11. Donations: Dr. Ranajit Mandal has spearheaded
12. Awards- ASGO- IIG, fund not yet received due to non- FCRA account which is under process.
13. Publications- Lancet Oncology, Cancers

Academic partnerships and contracts signed/in process

- BrasGyn (Brazil Gyn Oncology Group)
- APGOT (Asia Pacific Gyn oncology Trials group- inducted as a member 23rd July 2021)
- Cepheid (Industry)- for North Bengal point of care HPV project
- BDR Pharma- IPIROC study
- IGCS

- World ovarian cancer coalition- Every women study
- Ovarcome, USA- NuGenA project
- ASCO
- SENTICOL- GINECO
- INTERLACE- UCL
- DST for affiliation and DBT for GCIG-DBT co-funding mechanisms
- Suraksha Diagnostics

In Pipeline- Newcastle University, UK,
James Cook University Hospital, UK,
Imperial College London
Barts Cancer Institute/Royal London Hospital
London School of Hygiene and Tropical Medicine
Curie Institute, Paris

Institutional participation/ memberships (consider including external partners/ collaborators)- approached and proposed

- Army Command Hospital, Kolkata
- Civil Services Hospital, Kathmandu (IGCS training site)
- AIIMS and GTB, Delhi
- Lucknow
- CMC, Vellore
- ASTER, Bangalore
- SNU, Kolkata
- Bangladesh- National Institute for Cancer and Research
- TMH, Mumbai
- IICB, Kolkata

Grants written as a group

- CRUK- DBT- successful in obtaining seed funding- Resubmission to DBT
- ASCO- awarded but funds not received yet as no FCRA

Pipeline

- MRC Joint Global Health/ CARP
- Prepare for Wellcome team science/ CPH next year

1. Biobank- Training initiated with LIMS, physical location (Suraksha labs) - working towards accreditation.
2. KolGo Trg oversees office/ Friends of KolGo- UK association
3. Dedicated Server and IT support- Magic Nines
4. Website development done – WebSys- www.kolgotrg.org,
5. Social media- FB, Twitter
6. Clinical Trials. Gov domain: due to KolGO trials being multicentric
7. Bio RAP, CTRI, ICMR HSMC: all studies to go through this pathway

8. SOP and protocol development- Lead: Santanu Tripathi (KolGo Trg).
9. PPI group creation- Sarbojaya (CRUK and World ovarian cancer coalition- members represented in the meeting)
10. Manuscripts – In progress n=3, published- 2 (Lancet Oncology and Cancers)
11. Presentations in GCIg meetings
Ovarian, Phase 2 committee and Translational committee
12. IGCS presentations - poster
13. 6th OCCC GCIg 2021 (Ovarian cancer consortium conference)- October 2021
14. GCIg Spring meeting – June 2022
15. Trial updates

Sl no	Trial Name	Collaborators	Institutions	Status
1.	INTERLACE	UCL	CNCI and SGCCRI	Recruitment completed 4 from SGCCRI 6 from CNCI
2.	IPIROC		CNCI SGCCRI	Recruiting. 6 recruited till now
3.	SENTICOL- III	ARCAGY/ GINECO GROUP European Network of Gynaecological Oncological Trial Groups (ENGOT)	CNCI	Recruiting Recruited 2 till now. Patients are on follow-up now.
4.	NuGenA		CNCI	Recruiting Recruited 106, Tested 51
5.	HR-HIPEC		CNCI	Recruiting Recruited 11
6.	IPIROC		CNCI	Recruiting Recruited 7
7.	Every Woman Study- LMIC	WOCC and IGCS	1. CNCI, KOLKATA. 2. Saroj Gupta Cancer Research Centre, Kolkata 3. AIIMS New Delhi 4. KGMU Lucknow 5. UCMS & GTB Hospital: Delhi 6. Kalyan Singh Super Specialty Cancer Institute, Lucknow 7. Command	CTRI and HMSC submitted, awaiting approval

			Hospital, Kolkata	
8.	Precerca-I	Cepheid India and Manisha Nandy Foundation	CNCI Tea Gardens SNU	CTRI submitted. Protocol finalizing. MoUs Will start recruiting from November, 2022
9.	HOTROC		SGCCRI	Protocol finalizing

In pipeline

BIODIVERSITY
PARPMORE
TINMORE
PARP RAD
RECERCA
ROCK

Membership update – Total no. of members: 39

Founding Member 10
Annual Member 5
Life Member 22
Honorary member 2

**Annual membership lapsed- 7

KOLKATA GYNCOLOGICAL ONCOLOGY TRIALS & TRANSLATIONAL RESEARCH GROUP

37 Shyama Prasad Mukherjee Road
 CNCI, Room:404A
 Kolkata - 700026

Balance Sheet

1-Apr-2021 to 31-Mar-2022

Liabilities	Kolgo Trg 2021-22 - (from as at 31-Mar-2022	Assets	Kolgo Trg 2021-22 - (from 1- as at 31-Mar-2022
Capital Account	80022.61	Fixed Assets	154820.64
Reserves & Surplus		Computer and Laptop	96081.64
General Fund	80022.61	Computer and Peripherals (CRUK-DBT-CNCI)	26994.00
Loans (Liability)		Furniture & Fixtures	31745.00
Current Liabilities	1598728.00	Current Assets	1680098.47
Salary Payable	732210.00	Closing Stock	
Duties & Taxes	-14370.00	Loans & Advances (Asset)	-229320.80
Sundry Creditors		Sundry Debtors	1567.00
Biobanking_cloudlims Standard_payable	165000.00	Cash-in-hand	1896632.27
Consultancy Fees Payable		Bank Accounts	
GCIG Membership Fees Payable	125000.00	Input CGST Receivable	
Trial Insurance Payable	236000.00	Input SGST Receivable	
Unexpired Project Income	354888.00	Profession Tax Paid in Advance	220.00
		TDS(A.Y. 2022-23)	11000.00
Excess of income over expenditure	164168.50	Balance with Revenue Authority	8000.00
Opening Balance		TDS (AY 2020-21)	
Current Period	164168.50	TDS (AY 2021-22)	8000.00
Total	1842919.11	Total	1842919.11

Dated : 27th September, 2022
 Place : Kolkata
 UDIN : 22053912AVTBTV1293


In terms of our report of even date annexed herewith.
 For R. DAS & ASSOCIATES
 Chartered Accountants
 FRNo. 0318161E


 (RIP DAS)

Proprietor
 M. No. 053912




**Kolkata Gynecological Oncology
 Trials and Translational Research Group**




President

**Kolkata Gynecological Oncology
 Trials and Translational Research Group**



Secretary

**Kolkata Gynecological Oncology
 Trials and Translational Research Group**



Treasurer

KOLKATA GYNOCOLOGICAL ONCOLOGY TRIALS & TRANSLATIONAL RESEARCH GROUP

37 Shyama Prasad Mukherjee Road

CNCI, Room:404A

Kolkata - 700026

Income and Expenditure Statement

1-Apr-2021 to 31-Mar-2022

Particulars	Kolgo Trg 2021-22 - (from 1-Apr-2021 to 31-Mar-2022	Particulars	Kolgo Trg 2021-22 - (from 1- 1-Apr-2021 to 31-Mar-2022
Purchase Accounts		Indirect Incomes	2006068.87
Indirect Expenses	1841900.37	Annual Meet Participation	150000.00
Advertisement	3038.08	Annual Membership Fee	4000.00
Annual Meet 2022	151611.00	Bank Interest	11306.00
Audit Fees	6000.00	Donation Received	1548000.00
Bank Charges	4378.70	GCP Training	16000.00
Biobanking_cloudlms Standard	165000.00	Interest on IT Refund	1898.00
Carriage	4030.00	INTERLACE STUDY	174862.72
Consultancy Fees Paid	40000.00	Life Membership Fee	100000.00
Conveyance & Travelling	11615.00	Ro	2.15
Difference in Conversion Rate	9460.51		
Electrical Fittings	18850.00		
GCIG Membership Fees	240392.08		
GCP Training Expenses	27000.00		
Installation Charges	600.00		
Interest on GST	1416.00		
Interest on Profession Tax Enrolment Fee	25.00		
Interest on P Tax	253.00		
Late Fee of GST	1650.00		
Office Maintenance	13200.00		
Postage	160.00		
Printing and Stationery	1338.00		
Profession Tax Enrolment Fee	2500.00		
Projector Screen	1200.00		
Router	3532.00		
Salaries and Wages	880000.00		
Server Space	10500.00		
Societies Registration Fee (E District)	375.00		
TDS Filing Fee	3900.00		
Telephone Charges	876.00		
Trial Insurance	236000.00		
Website Hosting	3000.00		
Excess of income over expenditure	164168.50		
Total	2006068.87	Total	2006068.87

Dated : 27th September, 2022

Place : Kolkata

UDIN : 22053912AVTBT1293

In terms of our report of even date annexed herewith.

For R. DAS & ASSOCIATES

Chartered Accountants

FRNo. 0318161E

**Kolkata Gynecological Oncology
Trials and Translational Research Group**

Biman Chakrabarty

President

(RIP DAS)

(RIP DAS)

Proprietor

M. No. 053912



**Kolkata Gynecological Oncology
Trials and Translational Research Group**

Asima Mukhopadhyay

Secretary

**Kolkata Gynecological Oncology
Trials and Translational Research Group**

(Signature)

Treasurer

KOLKATA GYNCOLOGICAL ONCOLOGY TRIALS & TRANSLATIONAL RESEARCH GROUP


37 Shyama Prasad Mukherjee Road
 CNCI, Room:404A
 Kolkata - 700026

Receipts and Payments
 1-Apr-2021 to 31-Mar-2022

Receipts		Kolgo Trg 2021-22 - (from 1-Apr-2021)	Payments	
		1-Apr-2021 to 31-Mar-2022	Kolgo Trg 2021-22 - (from 1-Apr-2021)	
			1-Apr-2021 to 31-Mar-2022	
Opening Balance		18023.84	Current Liabilities	577958.87
Bank Accounts	14697.84		Consultancy Fees Payable	36000.00
Cash-in-hand	3326.00		Salary Payable	146620.00
Current Liabilities		18720.00	Duties & Taxes	38606.87
Duties & Taxes	18720.00		Sundry Creditors	356732.00
Current Assets		930184.00	Current Assets	3642.00
Sundry Debtors	930184.00		Profession Tax Paid in Advance	110.00
Indirect Incomes		1681204.87	Loans & Advances (Asset)	3532.00
Annual Membership Fee	4000.00		Indirect Expenses	197544.57
Bank Interest	11306.00		Advertisement	3038.08
Donation Received	1548000.00		Audit Fees	6000.00
GCP Training	16000.00		Bank Charges	2976.41
Interest on IT Refund	1898.00		Carriage	4030.00
Life Membership Fee	100000.00		Conveyance & Travelling	11615.00
Ro	0.87		GCIG Membership Fees	115392.08
Balance with Revenue Authority		29212.00	GCP Training Expenses	27000.00
TDS (AY 2020-21)	29212.00		Installation Charges	600.00
			Interest on GST	1416.00
			Interest on Profession Tax Enrolment Fee	25.00
			Interest on P Tax	253.00
			Late Fee of GST	1650.00
			Office Maintenance	13200.00
			Postage	160.00
			Printing and Stationery	1338.00
			Profession Tax Enrolment Fee	2500.00
			Projector Screen	1200.00
			Societies Registration Fee (E District)	375.00
			TDS Filing Fee	3900.00
			Telephone Charges	876.00
			Closing Balance	1898199.27
			Bank Accounts	1896632.27
			Cash-in-hand	1567.00
Total		2677344.71	Total	2677344.71


Dated : 27th September, 2022
 Place : Kolkata
 UDIN : 22053912AVTBTV1293

In terms of our report of even date annexed herewith.
 For R. DAS & ASSOCIATES
 Chartered Accountants
 ERNo. 0318161E



 (RIP DAS)
 Proprietor
 M. No. 053912




**Kolkata Gynecological Oncology
 Trials and Translational Research Group**


President

**Kolkata Gynecological Oncology
 Trials and Translational Research Group**


Secretary

**Kolkata Gynecological Oncology
 Trials and Translational Research Group**


Treasurer